Out of the Gate: Marsh & McLennan Slips

Goldman Sachs analyst Thomas V. Cholnoky, who previously did not rate Marsh & McLennan's stock, established a "Sell" rating on the company's shares and a $25 price target. Even though the shares have lost nearly 20 percent in the past three months, he still sees little to be excited about.

Marsh & McLennan, whose primary business is to collect brokerage fees for linking insurers with clients, said the company continues to face sinking prices for insurance policies. The insurance brokerage industry is suffering from too much competition for clients and employees, he said.

The New York-based company's shares trade at a premium to other brokers, which Cholnoky said is no longer warranted.

Shares of Marsh & McLennan slipped 9 cents to $26.56 in morning trading Tuesday.